Announcing Cochrane's new brand identity
Image I am delighted to announce the launch of Cochrane’s new website and organizational identity.
Cochrane Review compares two drugs used for treatment of macular degeneration
Image Cochrane Review shows how a cheaper alternative to licensed drug for treating eye disease has similar side effectsNeovascular macular degeneration is a progressive and chronic disease of the eye, and a leading cause of blindness in older people globally.
Image In a recent story, US-based Fox News discusses the publication of a number of major studies, including a Cochrane Review, a
Website for the 2015 Colloquium is now live!
Image The website for the 23rd Cochrane Colloquium, taking place in Vienna from 3-7 October 2015, is now live. Get the latest information on key dates, registration, and activities in the historic host city.
Tamiflu and Relenza: getting the full evidence picture
Since 2002, governments around the world have spent billions of dollars stockpiling neuraminidase inhibitors (NIs) such as Tamiflu® (oseltamivir) and Relenza® (zanamivir) in anticipation of an influenza pandemic. This
News
News
The Cochrane Collaboration is a charity (no. 1045921) and a company limited by guarantee (no. 03044323) registered in England & Wales. VAT registration number GB 718 2127 49.